Literature DB >> 17671853

[Posterior fossa hemangioblastomas].

M Gelabert González1.   

Abstract

INTRODUCTION: Hemangioblastomas are histologically benign lesions that comprise 1-2 % of primary nervous system tumours and 8-12 % of all posterior fossa lesions in the adult. They commonly occur in young adults with a peak incidence corresponding to the fourth decade of life.
METHODS: Twenty-two patients with 24 posterior fossa hemangioblastomas were identified, accounting for 6.4 % of all posterior fossa tumours surgically treated from January 1980 to January 2006.
RESULTS: There were 12 males and 10 females. The patients were aged from 18 to 58 years with an average age of 39.1. Tumors were located on cerebellar hemisphere (17), cerebellar vermis (4) and brain stem (1). Tumors were cyst in 16 cases, solid in 8 cases. Total tumor removal was achieved in 21 patients (95 %), and incomplete removal in 1 cases.
CONCLUSIONS: Hemangioblastomas are benign tumors of uncertain origin that are located predominantly in the posterior cranial fossa and the spinal cord. Although most hemangioblastomas are sporadic, they are associated with autosomally dominant von Hippel-Lindau (VHL) disease in approximately 25 % of cases. Most hemangioblastomas can be cured with surgical resection, and long-term recurrence rates seem to depend on the presence of VHL disease and multicentric lesions.

Entities:  

Mesh:

Year:  2007        PMID: 17671853

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  2 in total

1.  Surgical resection of cerebellar hemangioblastoma with enhanced wall thickness: A report of two cases.

Authors:  Zhenxing Sun; Dan Yuan; Yaxing Sun; Pengxiang Yan; Huancong Zuo
Journal:  Oncol Lett       Date:  2015-02-10       Impact factor: 2.967

2.  Cerebellar hemangioblastoma mimicking an aneurysm: A case report and literature review.

Authors:  Yu-Chen Ji; Yan Li; Jing-Xia Hu; Hong-Bo Zhang; Peng-Xiang Yan; Huan-Cong Zuo
Journal:  Oncol Lett       Date:  2016-08-08       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.